Hong Kong Shares Surge: TYK MEDICINES-B Soars Over 15% in Afternoon Trading on Key Drug Trial Results

Stock News07-21

Shares of TYK MEDICINES-B (02410) experienced a significant surge in afternoon trading, rising more than 15%. At the time of writing, the stock was up 12.37% to HK$8.54, with a turnover of HK$53.76 million.

The catalyst for the move was news from the 2026 ASCO conference, where the company presented interim analysis results from the ESAONA study in a Late-Breaking Abstract oral presentation. The study focused on its drug edotinib (TY-9591) as a first-line treatment for EGFR-mutated non-small cell lung cancer (NSCLC) patients with brain metastases.

An analysis highlighted that edotinib demonstrated superiority over osimertinib in a head-to-head trial for NSCLC patients with brain metastases. The drug is anticipated to be launched in the third quarter of 2026.

Product Differentiation and Market Potential

Previous research reports have noted that TY-9591 is the only third-generation EGFR-TKI globally to have conducted a head-to-head trial against osimertinib. The drug's development program also includes targeting the EGFR L858R mutation and exploring its use in combination with chemotherapy for first-line treatment of advanced NSCLC, expanding its potential beyond brain metastasis.

Projected Financial Impact

Forecasts suggest that TY-9591 could achieve peak sales exceeding 5 billion yuan under a neutral scenario. Revenue for the company over the next three years is expected to be primarily driven by the contributions from TY-9591.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1138336031?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-21 13:46","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1138336031","market":"nz","top_or_hot":-1,"title":"Hong Kong Shares Surge: TYK MEDICINES-B Soars Over 15% in Afternoon Trading on Key Drug Trial Results","media":"Stock News","content":"<p>Shares of <b>TYK MEDICINES-B</b> (<b>02410</b>) experienced a significant surge in afternoon trading, rising more than 15%. At the time of writing, the stock was up 12.37% to HK$8.54, with a turnover of HK$53.76 million.<br><br>\nThe catalyst for the move was news from the 2026 ASCO conference, where the company presented interim analysis results from the ESAONA study in a Late-Breaking Abstract oral presentation. The study focused on its drug edotinib (TY-9591) as a first-line treatment for EGFR-mutated non-small cell lung cancer (NSCLC) patients with brain metastases.<br><br>\nAn analysis highlighted that edotinib demonstrated superiority over osimertinib in a head-to-head trial for NSCLC patients with brain metastases. The drug is anticipated to be launched in the third quarter of 2026.<br><br>\n<b>Product Differentiation and Market Potential</b><br><br>\nPrevious research reports have noted that TY-9591 is the only third-generation EGFR-TKI globally to have conducted a head-to-head trial against osimertinib. The drug's development program also includes targeting the EGFR L858R mutation and exploring its use in combination with chemotherapy for first-line treatment of advanced NSCLC, expanding its potential beyond brain metastasis.<br><br>\n<b>Projected Financial Impact</b><br><br>\nForecasts suggest that TY-9591 could achieve peak sales exceeding 5 billion yuan under a neutral scenario. Revenue for the company over the next three years is expected to be primarily driven by the contributions from TY-9591.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Hong Kong Shares Surge: TYK MEDICINES-B Soars Over 15% in Afternoon Trading on Key Drug Trial Results</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHong Kong Shares Surge: TYK MEDICINES-B Soars Over 15% in Afternoon Trading on Key Drug Trial Results\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-07-21 13:46</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shares of <b>TYK MEDICINES-B</b> (<b>02410</b>) experienced a significant surge in afternoon trading, rising more than 15%. At the time of writing, the stock was up 12.37% to HK$8.54, with a turnover of HK$53.76 million.<br><br>\nThe catalyst for the move was news from the 2026 ASCO conference, where the company presented interim analysis results from the ESAONA study in a Late-Breaking Abstract oral presentation. The study focused on its drug edotinib (TY-9591) as a first-line treatment for EGFR-mutated non-small cell lung cancer (NSCLC) patients with brain metastases.<br><br>\nAn analysis highlighted that edotinib demonstrated superiority over osimertinib in a head-to-head trial for NSCLC patients with brain metastases. The drug is anticipated to be launched in the third quarter of 2026.<br><br>\n<b>Product Differentiation and Market Potential</b><br><br>\nPrevious research reports have noted that TY-9591 is the only third-generation EGFR-TKI globally to have conducted a head-to-head trial against osimertinib. The drug's development program also includes targeting the EGFR L858R mutation and exploring its use in combination with chemotherapy for first-line treatment of advanced NSCLC, expanding its potential beyond brain metastasis.<br><br>\n<b>Projected Financial Impact</b><br><br>\nForecasts suggest that TY-9591 could achieve peak sales exceeding 5 billion yuan under a neutral scenario. Revenue for the company over the next three years is expected to be primarily driven by the contributions from TY-9591.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4588","symbol_name":"碎股","start_time":0,"source_url":"","article_id":"1138336031","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1138336031","pubTimestamp":1784612808,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Shares of TYK MEDICINES-B (02410) experienced a significant surge in afternoon trading, rising more than 15%. At the time of writing, the stock was up 12.37% to HK$8.54, with a turnover of HK$53.76...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"159938":"医药","BK4588":"碎股","09939":"开拓药业-B","BK1515":"抗疫概念","BK1161":"生物科技","BK4585":"ETF&股票定投概念","BK1574":"生物医药B类股","IPOS":"Renaissance International IPO ETF","02410":"同源康医药-B","VXUS":"国际股票ETF-Vanguard","KCAI":"KraneShares China Alpha Index ETF"},"translate_title":"港股飙升：TYK MEDICINES-B 因关键药物试验结果在下午交易中飙升超过 15%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"159938":1,"IPOS":1,"VXUS":1,"KCAI":1,"09939":1,"02410":1},"content_text":"Shares of TYK MEDICINES-B (02410) experienced a significant surge in afternoon trading, rising more than 15%. At the time of writing, the stock was up 12.37% to HK$8.54, with a turnover of HK$53.76 million.\nThe catalyst for the move was news from the 2026 ASCO conference, where the company presented interim analysis results from the ESAONA study in a Late-Breaking Abstract oral presentation. The study focused on its drug edotinib (TY-9591) as a first-line treatment for EGFR-mutated non-small cell lung cancer (NSCLC) patients with brain metastases.\nAn analysis highlighted that edotinib demonstrated superiority over osimertinib in a head-to-head trial for NSCLC patients with brain metastases. The drug is anticipated to be launched in the third quarter of 2026.\nProduct Differentiation and Market Potential\nPrevious research reports have noted that TY-9591 is the only third-generation EGFR-TKI globally to have conducted a head-to-head trial against osimertinib. The drug's development program also includes targeting the EGFR L858R mutation and exploring its use in combination with chemotherapy for first-line treatment of advanced NSCLC, expanding its potential beyond brain metastasis.\nProjected Financial Impact\nForecasts suggest that TY-9591 could achieve peak sales exceeding 5 billion yuan under a neutral scenario. Revenue for the company over the next three years is expected to be primarily driven by the contributions from TY-9591.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"2","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.46.0","shortVersion":"4.46.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1138336031","isCrawlerRequest":true}